Narrative Update: DarioHealth
Analysts have maintained their price target for DarioHealth at $22.25, citing stable growth projections and recent adjustments to key financial metrics.
What's in the News
- DarioHealth announced the addition of six new employer clients, expanding its value-based care strategy by implementing a pricing model tied to member engagement and clinical outcomes (Client Announcements).
- The company’s Board of Directors initiated a strategic review following multiple unsolicited inquiries. The options under consideration include a sale, a merger, or continued stand-alone operations, with Perella Weinberg Partners serving as advisor (Considering Multiple Strategic Alternatives).
- DarioHealth closed a private placement, raising $17.5 million from 10 investors through the sale of common shares and pre-funded warrants (Private Placements).
- Five new contracts with self-insured employers launched, featuring the company’s full cardiometabolic suite and demonstrating ongoing demand for integrated digital health solutions (Client Announcements).
- The company executed a 1-for-20 stock split on August 28, 2025 (Stock Splits & Significant Stock Dividends).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $22.25.
- Discount Rate has decreased from 9.88% to 8.95%.
- Revenue Growth expectation remains steady at 18.28%.
- Net Profit Margin has declined slightly from 8.77% to 8.46%.
- Future P/E ratio has risen marginally from 14.99x to 15.14x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.